Sarepta Soars After FDA Staffer’s Exit Lifts Approval Hopes

  • Ron Farkas, reviewer critical of Sarepta drug, departed
  • Sarepta still awaits FDA decision on muscle disease treatment

Sarepta Therapeutics Inc. rose the most since June after a U.S. Food and Drug Administration reviewer who was critical of the drugmaker’s proposed treatment left the agency, potentially brightening prospects for approval of the medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.